NASDAQ:MLNDMillendo Therapeutics Stock Price, Forecast & News

Millendo Therapeutics' stock was trading at $6.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MLND stock has decreased by 69.9% and is now trading at $1.98. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Millendo Therapeutics.

Millendo Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Millendo Therapeutics.

Millendo Therapeutics Inc (NASDAQ:MLND) issued its earnings results on Friday, May, 8th. The company reported ($0.65) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.67) by $0.02. View Millendo Therapeutics' earnings history.

7 brokers have issued twelve-month price objectives for Millendo Therapeutics' stock. Their forecasts range from $2.00 to $26.00. On average, they anticipate Millendo Therapeutics' stock price to reach $13.33 in the next year. This suggests a possible upside of 573.4% from the stock's current price. View analysts' price targets for Millendo Therapeutics.

Media coverage about MLND stock has been trending extremely positive this week, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Millendo Therapeutics earned a media sentiment score of 4.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View the latest news aboutMillendo Therapeutics.

Millendo Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 442,000 shares, an increase of 43.6% from the April 30th total of 307,900 shares. Based on an average daily volume of 800,300 shares, the short-interest ratio is presently 0.6 days. Approximately 3.4% of the company's stock are short sold. View Millendo Therapeutics' Current Options Chain.

Some companies that are related to Millendo Therapeutics include Arbutus Biopharma (ABUS), Trevena (TRVN), IDEAYA Biosciences (IDYA), BIOFRONTERA AG/ADR (BFRA), Zynerba Pharmaceuticals (ZYNE), AVEO Pharmaceuticals (AVEO), Rockwell Medical (RMTI), Conatus Pharmaceuticals (CNAT), CELYAD SA/ADR (CYAD), Sierra Oncology (SRRA), Harrow Health (HROW), Savara (SVRA), AcelRx Pharmaceuticals (ACRX), Immunic (IMUX) and SUMMIT THERAPEU/S (SMMT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Applied Genetic Technologies (AGTC), Aileron Therapeutics (ALRN), Aquestive Therapeutics (AQST), Flexion Therapeutics (FLXN), Galmed Pharmaceuticals (GLMD), Gilead Sciences (GILD), Obseva (OBSV) and Outlook Therapeutics (OTLK).

Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."

Millendo Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.23%), State Street Corp (0.94%), Soleus Capital Management L.P. (0.78%), Geode Capital Management LLC (0.75%), JPMorgan Chase & Co. (0.18%) and Bank of New York Mellon Corp (0.15%).

MLND stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC.

MLND stock was acquired by a variety of institutional investors in the last quarter, including Soleus Capital Management L.P., BlackRock Inc., Geode Capital Management LLC, Dupont Capital Management Corp, Los Angeles Capital Management & Equity Research Inc., Trexquant Investment LP, Nuveen Asset Management LLC, and Wedbush Securities Inc..

Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MLND stock can currently be purchased for approximately $1.98.

Millendo Therapeutics has a market capitalization of $37.62 million and generates $290,000.00 in revenue each year. The company earns $-44,570,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis. Millendo Therapeutics employs 37 workers across the globe.

The official website for Millendo Therapeutics is www.millendo.com.

Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected]